Post by Bristol Myers Squibb on X
Bristol Myers Squibb@bmsnews
XMEDIA: The @US_FDA has granted Breakthrough Therapy Designation to our investigational EGFRxHER3 bispecific ADC for previously treated EGFR-mutant NSCLC. Read More: t.co

26 likes4 repliesPosted Aug 18, 2025